Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
11/08/2026 06:33
BRIEF-Dermapharm Holding - Confirms Full-Year Guidance For 2026 Aug 11 (Reuters) - Dermapharm Holding SE DMPG.DE:
DERMAPHARM H1 ADJUSTED EBITDA MARGIN 27.6%
DERMAPHARM H1 ADJUSTED EBITDA EUR 163.2 MILLION
DERMAPHARM H1 REVENUE EUR 591 MILLION
DERMAPHARM H1 EBITDA MARGIN 31.2%
DERMAPHARM H1 EBITDA EUR 184.5 MILLION
DERMAPHARM HOLDING - CONFIRMS FULL-YEAR GUIDANCE FOR 2026
Source text: ID:nEQ3Bggyca
Further company coverage: DMPG.DE
(Gdansk Newsroom)
(((Gdansk.newsroom@thomsonreuters.com; +48 58 7696600);))
Recent news on Dermapharm Holding SE
See all newsBrief: Dermapharm Confirms 2026 Forecast
Corrected: Germany's Dermapharm prelim H1 revenue rises, maintains outlook
Brief: Dermapharm Holding - Confirms Full-Year Guidance For 2026
Brief: Dermapharm Spokesperson - Dermapharm Is Engaged In A Constructive Dialogue With The Regulator
Refile: BUZZ-Dermapharm Holding slips after BaFin's audit